Synopsis:
Auro Laboratories’ shares jumped 20% as Q2 revenue rose 219% QoQ to ₹8.84 crore, turning net profit to ₹0.72 crore from a loss.
The shares of the Micro-Cap company specializing in the manufacturing of generic Active Pharmaceutical Ingredients (APIs), with a particular focus on anti-diabetic drugs such as Metformin HCl, hit a 20 percent upper circuit following their results, with a 219 percent rise in revenue.
With a market capitalization of Rs. 136.74 Crores on Thursday, the shares of Auro Laboratories Ltd hit a 20 percent upper circuit, reaching a high of Rs. 219.40 compared to its previous close of Rs. 182.85.
What Happened
Auro Laboratories Ltd, engaged in the manufacturing of generic Active Pharmaceutical Ingredients (APIs), with a particular focus on anti-diabetic drugs such as Metformin HCl, has announced its Q2 results as follows:
Its Revenue from operations rose by 185 percent YoY from Rs. 3.10 Crores in Q2FY25 to Rs. 8.84 Crores in Q2FY26, and it rose by 219 percent QoQ from Rs. 2.77 Crores in Q1FY26 to Rs. 8.84 Crores in Q2FY26.
Its Net Profit YoY rose by 100 percent from Rs. 0.36 Crores in Q2FY25 to Rs. 0.72 Crores in Q2FY26, and on a QoQ basis, from a loss of Rs. 0.11 Crores in Q1FY26, it turned to a profit of Rs. 0.72 Crores in Q2FY26. The earnings per share (EPS) for the quarterly period stood at Rs. 1.15, compared to negative Rs. 0.17 in the previous quarter.
Other Update
The Company’s API (Bulk Drugs) manufacturing facility in MIDC Tarapur, Maharashtra, has successfully cleared the World Health Organization (WHO) inspection. The facility has been awarded the WHO-GMP certificate by the Food & Drug Administration, Maharashtra, valid until September 30, 2028.
Company Overview & Others
Auro Laboratories Ltd. is an India-based company that manufactures Active Pharmaceutical Ingredients (APIs), intermediates, and generic formulations. The company specializes in anti-diabetic drugs, such as Metformin Hydrochloride, and also produces a range of other APIs and intermediates for various therapeutic areas.
The company was founded and incorporated in 1992 in Mumbai, with a manufacturing facility located at Tarapur, 120 Km from Mumbai. Since its inception, it has focused on providing quality pharmaceuticals while maintaining high manufacturing standards.
It has made its presence felt in international markets with a bulk of our production being exported to Southeast Asia, the Middle East, and several European Countries. Some of the countries they export to are Egypt, Germany, Malaysia, Singapore, South Africa, Brazil, Spain, and the United Kingdom.
Written by Sridhar J
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
